Vecabrutinib

N/A

Report date: 2023/05/05 17:41:38
NME

Base Information

Drug NameVecabrutinib
Drug Alias NameSNS-062
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsWaldenstrom MacroglobulinemiaLymphoma, Mantle-CellLymphoma, Follicular +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSunesis Pharmaceuticals IncBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSunesis Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsWaldenstrom MacroglobulinemiaLymphoma, Mantle-CellLymphoma, Follicular +[6] 

Other Information

ATC CodeN/A
Related LinksN/A